罕见血液疾病的药物设计与开发
Drug Design and Development for Rare Hematologic Diseases.
作者信息
Fattizzo Bruno, Capecchi Marco, Motta Irene
机构信息
SC Ematologia, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy.
Department of Oncology and Hemato-Oncology, University of Milan, 20122 Milan, Italy.
出版信息
Pharmaceuticals (Basel). 2023 Oct 16;16(10):1469. doi: 10.3390/ph16101469.
Abstract
The last decade has seen an exponential increase in therapeutic options for rare hematologic diseases [...].
摘要
在过去十年中，罕见血液疾病的治疗选择呈指数级增长[……]。
相似文献
1
Drug Design and Development for Rare Hematologic Diseases.罕见血液疾病的药物设计与开发
Pharmaceuticals (Basel). 2023 Oct 16;16(10):1469. doi: 10.3390/ph16101469.
2
Toxicities of novel therapies for hematologic malignancies.血液系统恶性肿瘤新型治疗药物的毒性。
Expert Rev Hematol. 2020 Mar;13(3):241-257. doi: 10.1080/17474086.2020.1728249. Epub 2020 Feb 17.
3
What Is Different in Acute Hematologic Malignancy-Associated ARDS? An Overview of the Literature.急性血液恶性肿瘤相关 ARDS 有何不同？文献概述。
Medicina (Kaunas). 2022 Sep 3;58(9):1215. doi: 10.3390/medicina58091215.
4
Biological Therapy of Hematologic Malignancies: Toward a Chemotherapy- free Era.血液系统恶性肿瘤的生物治疗：迈向无化疗时代。
Curr Med Chem. 2019;26(6):1002-1018. doi: 10.2174/0929867324666171006144725.
5
Hematologic Complications of Tuberculosis.结核病的血液学并发症。
Microbiol Spectr. 2016 Dec;4(6). doi: 10.1128/microbiolspec.TNMI7-0004-2016.
6
[The spleen in hematologic malignancies].[血液系统恶性肿瘤中的脾脏]
Ther Umsch. 2013 Mar;70(3):163-9. doi: 10.1024/0040-5930/a000385.
7
Fecal Microbiota Transplant for Hematologic and Oncologic Diseases: Principle and Practice.用于血液学和肿瘤学疾病的粪便微生物群移植：原理与实践
Cancers (Basel). 2022 Jan 29;14(3):691. doi: 10.3390/cancers14030691.
8
Chemotherapy and Beyond: Infections in the Era of Old and New Treatments for Hematologic Malignancies.化疗及其他：血液恶性肿瘤新旧疗法时代的感染。
Infect Dis Clin North Am. 2019 Jun;33(2):289-309. doi: 10.1016/j.idc.2019.01.001. Epub 2019 Mar 30.
9
Future of monoclonal antibodies in the treatment of hematologic malignancies.单克隆抗体在血液系统恶性肿瘤治疗中的未来
Cancer Control. 2002 Mar-Apr;9(2):152-66. doi: 10.1177/107327480200900207.
10
Arsenic derivatives in hematologic malignancies: a role beyond acute promyelocytic leukemia?血液系统恶性肿瘤中的砷衍生物：其作用是否超出急性早幼粒细胞白血病？
Hematol Oncol. 2006 Dec;24(4):181-8. doi: 10.1002/hon.787.
本文引用的文献
1
Primary and secondary immune thrombocytopenia (ITP): Time for a rethink.原发性和继发性免疫性血小板减少症（ITP）：是时候重新思考了。
Blood Rev. 2023 Sep;61:101112. doi: 10.1016/j.blre.2023.101112. Epub 2023 Jun 29.
2
Systemic mastocytosis: 2023 update on diagnosis and management in adults.系统性肥大细胞增生症：成人诊断与治疗的 2023 年更新。
Expert Opin Emerg Drugs. 2023 Dec;28(3):153-165. doi: 10.1080/14728214.2023.2221028. Epub 2023 Jun 6.
3
Therapeutic perspective for children and young adults living with thalassemia and sickle cell disease.治疗地中海贫血症和镰状细胞病患儿及青少年的新视角。
Eur J Pediatr. 2023 Jun;182(6):2509-2519. doi: 10.1007/s00431-023-04900-w. Epub 2023 Mar 31.
4
Interpreting Iron Homeostasis in Congenital and Acquired Disorders.解读先天性和后天性疾病中的铁稳态
Pharmaceuticals (Basel). 2023 Feb 21;16(3):329. doi: 10.3390/ph16030329.
5
Rise of the planet of rare anemias: An update on emerging treatment strategies.罕见贫血症领域的崛起：新兴治疗策略的最新进展
Front Med (Lausanne). 2023 Jan 9;9:1097426. doi: 10.3389/fmed.2022.1097426. eCollection 2022.
6
Updates on Novel Non-Replacement Drugs for Hemophilia.血友病新型非替代药物的最新进展。
Pharmaceuticals (Basel). 2022 Sep 23;15(10):1183. doi: 10.3390/ph15101183.
7
Aplastic Anemia as a Roadmap for Bone Marrow Failure: An Overview and a Clinical Workflow.再生障碍性贫血作为骨髓衰竭的路线图：概述和临床工作流程。
Int J Mol Sci. 2022 Oct 4;23(19):11765. doi: 10.3390/ijms231911765.
8
Complement System as a New Target for Hematopoietic Stem Cell Transplantation-Related Thrombotic Microangiopathy.补体系统作为造血干细胞移植相关血栓性微血管病的新靶点
Pharmaceuticals (Basel). 2022 Jul 9;15(7):845. doi: 10.3390/ph15070845.
9
Novel Therapies to Address Unmet Needs in ITP.解决免疫性血小板减少症未满足需求的新型疗法。
Pharmaceuticals (Basel). 2022 Jun 23;15(7):779. doi: 10.3390/ph15070779.
10
Pharmacological Induction of Fetal Hemoglobin in β-Thalassemia and Sickle Cell Disease: An Updated Perspective.β地中海贫血和镰状细胞病中胎儿血红蛋白的药理学诱导：最新观点
Pharmaceuticals (Basel). 2022 Jun 16;15(6):753. doi: 10.3390/ph15060753.
Zotero 插件